Showing 1-10 of about 125 articles.
Bone Therapeutics SA
Regulated information Gosselies, Belgium, 23 April 2019, 7 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in...
Bone Therapeutics SA
Information réglementée Gosselies, Belgique, le 23 avril 2019, 7h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à...
Bone Therapeutics SA
Regulated information Gosselies, Belgium, 28 March 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs...
Bone Therapeutics SA
Information réglementée Gosselies, Belgique, le 28 mars 2019, 07h00 CET - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à...
Bone Therapeutics SA
Press release Gosselies, Belgium, 18 March 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in...
Bone Therapeutics SA
Press Release Gosselies, Belgium, 12 March 2019, 8am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in...
Bone Therapeutics SA
Communiqué de presse Gosselies, Belgique, le 12 mars 2019, 8h00 CET - BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE, éligible PEA-PME), société de thérapie cellulaire osseuse qui...
Bone Therapeutics SA
Information réglementée Gosselies, Belgique, le 5 mars 2019, 07h00 CET - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à...
Bone Therapeutics SA
Regulated information Gosselies, Belgium, 5 March 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in...
Bone Therapeutics SA
Regulated Information Significant progress across all areas of the business Positioned to move the clinical pipeline into late-stage development Proprietary, optimised commercial...
Showing 1-10 of about 125 articles.
